Alligator Bioscience informs that dosing has started in a second clinical phase I study with the CD40 Agonistic Immuno-Oncology Antibody ADC-1013- Janssen assumes responsibility for all future clinical studiesRead more »
- 9 November, 2016 - 13 November, 2016SITC, National Harbor, USA
Alligator Bioscience has a broad project portfolio with several antibody-based pharmaceuticals in immuno-oncology. Several of these R&D projects are operated in-house. The company's most advanced project, ADC-1013, is in clinical Phase I and is being developed together with partner Janssen Biotech.